Clik here to view.
Biotech vets raise $67M to develop targeted activators for cancer
Delphia Therapeutics said Thursday that it raised $67 million to develop targeted cancer therapies that overactivate drivers of cancer, defying the norm established by decades of cancer drug...
View ArticleClik here to view.
Novartis makes a $1B radiopharma deal, buying Mariana Oncology
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B. The move, which...
View ArticleClik here to view.
As it cuts costs and pipeline, Bristol Myers hands back a cancer drug to...
Bristol Myers Squibb will give back a preclinical cancer drug to Schrödinger, returning the SOS1 inhibitor that was part of a 2020 deal between the companies. Chris Boerner The move is part of a...
View ArticleContext Therapeutics' $100M placement; Blueprint raises guidance for rare...
Plus, news about Novocure and Corvus: Context Therapeutics’ $100M PIPE: Nextech led the private placement, and other investors like Ally Bridge Group took part. The solid tumor biotech also said the...
View ArticleAvid Bio fielding client inquiries due to China bill; Oxford Bio wants to...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Avid Bioservices has detected an uptick in client interest in the...
View ArticleFDA asks for more data on Dupixent in COPD in move that could delay a decision
The FDA wants more info on Regeneron and Sanofi’s blockbuster Dupixent before it decides whether to approve the treatment for some patients with chronic obstructive pulmonary disease, or COPD. That...
View ArticleModerna sticks to long-term strategy in first-quarter update, ends pact with...
Moderna’s shift to a more “restrained” posture was on full display Thursday morning during its first-quarter earnings update. CEO Stéphane Bancel and his team stayed away from making bold promises like...
View ArticleEmergent to shut facilities and lay off workers as part of new CEO’s roadmap
Newly appointed CEO Joe Papa outlined his vision for Emergent BioSolutions, which includes winding down two facilities and laying off 300 employees to save $80 million. According to an AlphaSense...
View ArticleClik here to view.
Novo nabs over a third of diabetes market, a year ahead of schedule
Novo Nordisk’s GLP-1 drugs may have been the center of attention during its first-quarter earnings call, but the company’s broader diabetes portfolio beat its target for a greater global market stake...
View ArticleClik here to view.
ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to...
The integrity of the FDA’s accelerated approval process should be called into question if the agency grants full approval to treatments that have failed their required confirmatory trials, the chief...
View ArticleAstraZeneca's Calquence hits endpoint in first-line mantle cell lymphoma trial
AstraZeneca is working on moving its BTK inhibitor Calquence into earlier stages of mantle cell lymphoma, releasing what it calls positive interim results from a Phase 3 trial. The combo of Calquence...
View ArticlePharma companies soften tone on full IRA impact
Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on...
View ArticleAmgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work
Amgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the company “very encouraged,” and it planned to rapidly move forward with a final-stage program as well as...
View ArticleClik here to view.
Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite
Lonnel Coats → Lexicon Pharmaceuticals CEO Lonnel Coats will retire July 7, 10 years to the day after accepting the job. Lexicon overcame numerous regulatory obstacles with its SGLT1/2 inhibitor...
View ArticleBipartisan draft bill would pay hospitals more to combat drug shortages
The Senate Finance Committee released a new bipartisan draft legislation on Friday morning that would incentivize generic manufacturers and healthcare providers, like hospitals and clinics, to mitigate...
View ArticleClik here to view.
AEON fails another migraine trial, shares halve as company reviews options
AEON Biopharma said its botulinum toxin treatment candidate failed a Phase 2 migraine study at the planned interim analysis. The company’s share price $AEON was halved in premarket trading on Friday....
View ArticleRoyalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering
Plus, news about Soleno, Novo Nordisk and Cardior Pharmaceuticals: Royalty Pharma pays Arrowhead Pharmaceuticals: The $50 million milestone payment comes after the completed enrollment of a Phase 3...
View ArticleRo CEO Zachariah Reitano talks GLP-1 drug pricing, shortages and compounded...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The fight to dominate the market for weight loss shots has never been hotter, but drugmakers still can’t...
View ArticleClik here to view.
CG Oncology touts interim Phase 3 bladder cancer data as it gears up to...
An experimental oncolytic virus therapy developed by CG Oncology helped clear tumors in 75% of bladder cancer patients in a Phase 3 study. The therapy, known as cretostimogene grenadenorepvec, or creto...
View ArticleFTC wants more information on Novo-Catalent deal in antitrust review
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. Both the...
View Article